Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (818)	7/25/2005 12:21:25 PM
From: richardred	Respond to of 7243

I have a suspicion IVAX might have been one of those companies! >The Generics division continued its very satisfactory development in the second quarter. In fact, the success of its bestseller in the United States, the DuoNeb® inhaler for treating chronic obstructive pulmonary disease (COPD), has prompted five generics companies to apply to the U.S. Food and Drug Administration (FDA) for approval to market their generic versions of this value-added product before its patent expires in June 2022. An approval from the FDA, if any, remains subject to the outcome of the patent litigation filed by Merck, and Merck is using all legal means to vigorously defend its patent